Brian S Finkelman1, Benjamin French, Luanne Bershaw, Stephen E Kimmel. 1. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
PURPOSE: Patients starting warfarin often experience lengthy dose-titration periods, when they are at high risk for bleeding and thromboembolism. However, relatively little is known about why some patients take longer than others to reach maintenance dose. Thus, we sought to identify social, clinical, and genetic factors associated with prolonged time to maintenance dose (TTM). METHODS: We conducted a time-to-event analysis, using a prospective cohort of patients initiating warfarin (N = 390). Additionally, we examined whether changes in post-initiation factors were associated with TTM. Finally, we performed a secondary analysis in a subcohort (N = 156) assessing the effect of adherence on TTM. RESULTS: No genetic or post-initiation factors were significantly associated with TTM. However, previous use of warfarin [hazard ratio (HR) = 0.64; 95% confidence interval (CI) 0.46, 0.88], current smoking status (HR = 0.61; 95%CI 0.39, 0.96), fewer than four doctor's visits in the previous year (HR = 0.63 vs 4-12 visits; 95%CI 0.46, 0.88), and worse general health status (HR = 0.63; 95%CI 0.47, 0.84) were significantly associated with longer TTM. Use of illegal injectable drugs (HR = 2.51; 95%CI 1.17, 5.39) was associated with shorter TTM. On secondary analysis, the HR for better adherence and TTM was 1.70 (95%CI 0.88, 3.27). CONCLUSIONS: Time to maintenance dose was associated with pre-existing behavioral factors, health care utilization, and health quality but not clinical comorbidities or genetic factors in patients initiating warfarin. Future studies are needed to determine whether warfarin patients with prolonged TTM would have better outcomes on alternative agents.
PURPOSE:Patients starting warfarin often experience lengthy dose-titration periods, when they are at high risk for bleeding and thromboembolism. However, relatively little is known about why some patients take longer than others to reach maintenance dose. Thus, we sought to identify social, clinical, and genetic factors associated with prolonged time to maintenance dose (TTM). METHODS: We conducted a time-to-event analysis, using a prospective cohort of patients initiating warfarin (N = 390). Additionally, we examined whether changes in post-initiation factors were associated with TTM. Finally, we performed a secondary analysis in a subcohort (N = 156) assessing the effect of adherence on TTM. RESULTS: No genetic or post-initiation factors were significantly associated with TTM. However, previous use of warfarin [hazard ratio (HR) = 0.64; 95% confidence interval (CI) 0.46, 0.88], current smoking status (HR = 0.61; 95%CI 0.39, 0.96), fewer than four doctor's visits in the previous year (HR = 0.63 vs 4-12 visits; 95%CI 0.46, 0.88), and worse general health status (HR = 0.63; 95%CI 0.47, 0.84) were significantly associated with longer TTM. Use of illegal injectable drugs (HR = 2.51; 95%CI 1.17, 5.39) was associated with shorter TTM. On secondary analysis, the HR for better adherence and TTM was 1.70 (95%CI 0.88, 3.27). CONCLUSIONS: Time to maintenance dose was associated with pre-existing behavioral factors, health care utilization, and health quality but not clinical comorbidities or genetic factors in patients initiating warfarin. Future studies are needed to determine whether warfarinpatients with prolonged TTM would have better outcomes on alternative agents.
Authors: Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton Journal: Pharmacogenomics Date: 2008-05 Impact factor: 2.533
Authors: Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford Journal: Am Heart J Date: 2006-03 Impact factor: 4.749
Authors: H Schelleman; Z Chen; C Kealey; A S Whitehead; J Christie; M Price; C M Brensinger; C W Newcomb; C F Thorn; F F Samaha; S E Kimmel Journal: Clin Pharmacol Ther Date: 2007-02-28 Impact factor: 6.875
Authors: S E Kimmel; J Christie; C Kealey; Z Chen; M Price; C F Thorn; C M Brensinger; C W Newcomb; A S Whitehead Journal: Pharmacogenomics J Date: 2007-02-27 Impact factor: 3.550
Authors: Carmel Kealey; Zhen Chen; Jason Christie; Caroline F Thorn; Alexander S Whitehead; Maureen Price; Frederick F Samaha; Stephen E Kimmel Journal: Pharmacogenomics Date: 2007-03 Impact factor: 2.533
Authors: Stephen E Kimmel; Zhen Chen; Maureen Price; Catherine S Parker; Joshua P Metlay; Jason D Christie; Colleen M Brensinger; Craig W Newcomb; Frederick F Samaha; Robert Gross Journal: Arch Intern Med Date: 2007-02-12
Authors: Theresa I Shireman; Jonathan D Mahnken; Patricia A Howard; Timothy F Kresowik; Qingjiang Hou; Edward F Ellerbeck Journal: Chest Date: 2006-11 Impact factor: 9.410
Authors: Catherine S Parker; Zhen Chen; Maureen Price; Robert Gross; Joshua P Metlay; Jason D Christie; Colleen M Brensinger; Craig W Newcomb; Frederick F Samaha; Stephen E Kimmel Journal: J Gen Intern Med Date: 2007-06-22 Impact factor: 5.128
Authors: B F Gage; C Eby; J A Johnson; E Deych; M J Rieder; P M Ridker; P E Milligan; G Grice; P Lenzini; A E Rettie; C L Aquilante; L Grosso; S Marsh; T Langaee; L E Farnett; D Voora; D L Veenstra; R J Glynn; A Barrett; H L McLeod Journal: Clin Pharmacol Ther Date: 2008-02-27 Impact factor: 6.875
Authors: Brian S Finkelman; Benjamin French; Luanne Bershaw; Colleen M Brensinger; Michael B Streiff; Andrew E Epstein; Stephen E Kimmel Journal: Pharmacoepidemiol Drug Saf Date: 2016-07-26 Impact factor: 2.890